Skip to content
  • Home
  • About Us
  • Services
  • Courses
  • Online Learning
  • News and Events
  • Contact Us
  • Home
  • About Us
  • Services
  • Courses
  • Online Learning
  • News and Events
  • Contact Us

Reviopharma Courses

  1. Home>
  2. Products>
  3. Reviopharma Courses
  • View:
  • 12
  • 24
  • All
  • Regulatory Framework for Advanced Therapies
    • Regulatory Framework for Advanced Therapies
    • Reviopharma Courses
    • Regulatory Framework for Advanced Therapies

    • 150,00 €
    • An overview of the European Legislation for Advanced Therapies Medicinal Products (ATMPs), displaying the different Regulations and Directives that define and classify advanced therapies, the marketing authorisation procedure of ATMPs at EMA, compassionate use and hospital exemption.
    • Add to cart
  • Interactions with EMA during ATMPs Development
    • Interactions with EMA during ATMPs Development
    • Reviopharma Courses
    • Interactions with EMA during ATMPs Development

    • 150,00 €
    • A walkthrough of different interactions and procedures available at the EMA to support the development of Advanced Therapy Medicinal Products (ATMPs) such as ATMP Classification Procedure, PRIME Scheme, Orphan Designation, Innovation Task Force meetings and Scientific Advice. Their requirements, how to apply for them and how developers would benefit. Overview on different national Scientific Advice procedures.
    • Add to cart
  • AVAILABLE ON ORDER – CMC Quality Challenges for Cell Therapy Products
    • AVAILABLE ON ORDER – CMC Quality Challenges for Cell Therapy Products
    • Reviopharma Courses
    • AVAILABLE ON ORDER – CMC Quality Challenges for Cell Therapy Products

    • 150,00 €
    • Discussing the most common quality challenges faced in the development of Advanced Therapy Medicinal Products: Starting Materials, Characterisation, Comparability, Potency and Viral Safety. Considerations to work around them to avoid possible issues.
    • Add to cart
  • AVAILABLE ON ORDER – Good manufacturing practices for ATMPs (Part IV).
    • AVAILABLE ON ORDER – Good manufacturing practices for ATMPs (Part IV).
    • Reviopharma Courses
    • AVAILABLE ON ORDER – Good manufacturing practices for ATMPs (Part IV).

    • 150,00 €
    • Reviewing the Good Manufacturing Practices requirements for ATMPs as displayed in the GMP Guidelines: EudraLex Volume 4, Part IV: Good Manufacturing Practice specific to Advanced Therapy Medicinal Product.
    • Add to cart
  • AVAILABLE ON ORDER – Clinical Trial Application and Investigational Dossier
    • AVAILABLE ON ORDER – Clinical Trial Application and Investigational Dossier
    • Reviopharma Courses
    • AVAILABLE ON ORDER – Clinical Trial Application and Investigational Dossier

    • 150,00 €
    • An explanation on the Clinical Trial Application (CTA) procedure with the types of documents and information to be included. The implications of the new Clinical Trials Information System (CTIS) and the content of the CTA, the Investigational Medicinal Product Dossier (IMPD) and Amendments on these documents.
    • Add to cart
  • AVAILABLE ON ORDER – Concepts on Advanced Therapies EU
    • AVAILABLE ON ORDER – Concepts on Advanced Therapies EU
    • Reviopharma Courses
    • AVAILABLE ON ORDER – Concepts on Advanced Therapies EU

    • 150,00 €
    • A scientific look on the different types of advanced therapies: gene therapies, somatic cell therapies, tissue engineered products and combined products. Examples of previous advanced therapies approved by EMA and cases studies of classifications of ATMPs.
    • Add to cart

Recent Posts

  • New FDA Guidance on Safety Testing of Human Allogeneic Cells
  • Insights on the New EU Health Technology Assessment Regulation (HTAR)
  • EMA’s SME Office 2023 Annual Report
  • New Gene Therapy for Children with Metachromatic Leukodystrophy Approved by FDA
  • Scientific Explorer: EMA’s AI Tool to Improve Scientific Advice

Recent Comments

  1. FDA Approves First Treatment for Rare Inherited Blood Disorder - Reviopharma on Expedited programs for regenerative medicine therapies for serious conditions
  2. EMA's 2022 Annual Report published - Reviopharma on EMA’s 2022 Highlights on Human Medicines and Advanced Therapies

Revio is a Regulatory Affairs Consultancy – Created to support biopharmaceutical companies and public institutions, working with Advanced Therapy Medicinal Products (ATMPs)

Facebook-f Twitter Pinterest Linkedin

About

Home

About Us

Services

News & Events

Contact Us

Contact

TELEPHONES

+34 656 659 636

EMAIL

regaffairs@reviopharma.com

Legal

Cookies Policy

Data Protection

Legal Notice

Privacy policy

Social Networks

Copyright © 2024 – All Right Reserved – Powered by: Headteam.marketing

×

Cart